Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 182

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 8
Chunk 182
---
    —

    792,878

    Grant and recognition of   stock options

    —

    —

    2,735,305

    —

    —

    —

    —

    2,735,305

    Recognition of parent stock   options

    —

    —

    106,829

    —

    —

    —

    —

    106,829

    Balance at December 31, 2024

    3,963,045

    $
    40

    $
    125,227,389

    —

    $
    —

    $
    (631,576
    )
     
    $
    (144,181,735
    )
     
    $
    (19,585,882
    )

See accompanying notes to consolidated financial statements. 

 72

MiNK THERAPEUTICS, INC. AND SUBSIDIARIES 

CONSOLIDATED STATEMENT OF CASH FLOWS 

    For the Year EndedDecember 31,

    2024

    2023

    Cash flows from operating activities:

    Net loss
     
    $
    (10,784,802
    )
     
    $
    (22,457,859
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Depreciation

    215,437

    204,617

    Share-based compensation

    1,810,226

    3,860,366

    Gain on deconsolidation

    (185,351
    )

    —

    Gain on forgiveness of liability

    (1,788,204
    )

    (266,780
    )

    Change in fair value of related party note

    638,046

    —

    Interest accrued on related party note

    79,444

    —

    Changes in operating assets and liabilities:

    Prepaid expenses

    (194,173
    )

    245,589

    Accounts payable

    (1,182,414
    )

    (1,917,557
    )

    Accrued liabilities and other current liabilities

    (393,771
    )

    2,025,124

    Other operating assets and liabilities

    2,230,086

    2,543,988

    Net cash used in operating activities

    (9,555,476
    )

    (15,762,512